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Abstract: Background: Virtual reality-based therapy (VRBT) is a novel therapeutic approach to be
used in women with fibromyalgia syndrome (FMS). The aim of our study is to assess the effect of
VRBT to reduce the impact of FMS in outcomes such as pain, dynamic balance, aerobic capacity,
fatigue, quality of life (QoL), anxiety and depression. Methods: Systematic review with meta-analysis
was conducted from a bibliographic search in PubMed, Scopus, PEDro, Web of Science and CINAHL
until April 2021 in accordance with PRISMA guidelines. We included randomized controlled trials
(RCTs) that compare VRBT versus others to assess the mentioned outcomes in women with FMS.
Effect size was calculated with standardized mean difference (SMD) and its 95% confidence interval
(95% CI). Results: Eleven RCTs involving 535 women with FMS were included. Using the PEDro
scale, the mean methodological quality of the included studies was moderate (6.63 ± 0.51). Our
findings showed an effect of VRBT on the impact of FMS (SMD −0.62, 95% CI −0.93 to −0.31); pain
(SMD −0.45, 95% CI −0.69 to −0.21); dynamic balance (SMD −0.76, 95% CI −1.12 to −0.39); aerobic
capacity (SMD 0.32, 95% CI 0.004 to 0.63); fatigue (SMD −0.58, 95% CI −1.02 to −0.14); QoL (SMD
0.55, 95% CI 0.3 to 0.81); anxiety (SMD −0.47, 95% CI −0.91 to −0.03) and depression (SMD −0.46,
95% CI −0.76 to −0.16). Conclusions: VRBT is an effective therapy that reduces the impact of FMS,
pain, fatigue, anxiety and depression and increases dynamic balance, aerobic capacity and quality
of life in women with FMS. In addition, VRBT in combination with CTBTE showed a large effect in
reducing the impact of FMS and fatigue and increasing QoL in these women.
Keywords: fibromyalgia; virtual reality; physiotherapy; pain; fatigue; quality of life; meta-analysis
1. Introduction
Fibromyalgia syndrome (FMS) is a chronic disease of unknown etiology that courses
with generalized and diffuse non-inflammatory pain and hyperalgesia in different human
body points [1]. Other FMS symptoms are joint stiffness [2], generalized fatigue [3], im-
paired balance [4], anxiety and depression [5], and emotional overload [6] that reduces
functional capacity [7] personal autonomy, social relationships [8] and quality of life
(QoL) [9,10]. The global prevalence of FMS ranges between 2% and 8% of the popula-
tion [11], mainly affects women (61–90%) [12] aged 50 years and over [13] and involve a
large consumption of social and health resources [14]. The negative impact of FMS has
turned FMS into a public health problem that requires the search for a therapeutic approach
to reduce the negative impact of FMS symptoms [15].
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Although the pathogenesis of FMS is unknown, the mechanisms responsible for dys-
functional pain in FMS, without having identifiable tissue lesions, are mainly related to
disorders of the central nervous system (CNS) that may explain diffuse musculoskeletal
pain [16]. Several studies have reported numerous changes in the brain cortex and spinal
cord descending tracts (i.e., descending pain modulatory system) in patients with FMS
producing central sensitization (CS) [17] and deficits in pain inhibitory mechanisms [18].
Several studies have shown that patients with FMS present hyperactivity and hyper-
excitability of their CNS, suggesting that it is supported by continuous nociceptive periph-
eral inputs [19]. Recent neuroimaging and biochemical studies have shown a reduction
in serotonin (5HT) and noradrenalin (NA) in cerebrospinal fluid [20] that may support
continuous and widespread pain in FMS due to dysfunction in the descending inhibitory
systems [21]. In addition, the activity of the insula lobe was shown to increase, producing
higher levels of the neurotransmitter glutamate in the posterior insula, which has been
associated with chronic pain [22]. Studies have reported evidence regarding peripheral
neurogenic inflammation in patients with FMS, compared to healthy subjects, due to the
presence of different proinflammatory peptides from the nerve terminals of peptidergic
C-fibers, including substance P, calcitonin gene-related protein and neurokinin A [22], all
of which are related to vasodilatation and an increase in vascular permeability responsible
for maintaining pain in FMS [23].
In recent years, numerous therapeutic proposals have been implemented in an attempt
to reduce the symptoms and the impact of FMS [14]. In addition to pharmacotherapy,
conservative non-pharmacological interventions based on physiotherapy, conventional
therapy (CT), or physical exercise are another modality in the treatment of FMS [24]. Re-
cent studies have highlighted active physical training as an effective therapy to improve
balance [25], pain [26], muscle fatigue [27], anxiety [28] and QoL [29], among others, in
patients with FMS. However, with the aim to get an increasing in the effect of CT, new
technologies have been used. For example, virtual reality-based therapy (VRBT) has ex-
perienced growth as a method for physical and cognitive training, showing benefits in
different contexts [30]. Virtual reality (VR) technology enables patients to be included in a
virtual environment similar to the real world through a computer and interact with it [31].
Immersive VR (iVR) uses headsets to display 3D digital images at 360◦ that simulate any
scenario with high realism, allowing patients to interact with this virtual environment
using a hand controller or their own hands [32]. Non-immersive VR (niVR) is considered
more accessible and inexpensive than iVR and enables patients to visualize virtual environ-
ments in 2D projected onto a screen and interact with them through the use of a mouse,
keyboard or joysticks [33,34]. VRBT is considered a useful intervention along with CT
for neurological [35] or musculoskeletal disorders [36] that can be used at home, thereby
favoring patient accessibility to physiotherapy protocols (telephysiotherapy), which has
been especially important during the COVID-19 pandemic [37].
The usability and feasibility of VRBT in CT protocols with promising results in the
management of pain, anxiety or mood states have been shown [38]. For example, in patients
with FMS, VRBT has allowed specific, intensive, multisensory and active therapies with
quick feedback in different environments and situations to be performed that increased the
motivation of the patient [39] and adherence to the therapy [40]. However, the absence of a
systematic review (SR) that unifies the available knowledge on the use and effects of VRBT
in patients with FMS may limit the impact of VRBT use. Therefore, the aim of our research
is to assess the effect of virtual reality-based therapy (VRBT) reduce the disabling impact of
fibromyalgia syndrome (FMS). In addition, to know if the effect shown by VRBT is greater
when VRBT is used alone or in combination with other therapies on FMS.
J. Pers. Med. 2021, 11, 1167 3 of 22
2. Materials and Methods
2.1. Protocol Design
This systematic review is reported in accordance with the preferred reporting items
for systematic reviews and meta-analyses (PRISMA) statement [41] and it was, previously
registered in PROSPERO: CRD42021225635.
2.2. Search Strategy and Data Sources
Two authors (I.C.-P. and M.C.O.-P.), independently, performed a bibliographical search
in PubMed Medline, Web of Science (WOS), Scopus, CINAHL Complete and PEDro (Phys-
iotherapy Evidence Database) to select articles published up to April 2021. The authors
reviewed the reference lists from retrieved full-text studies and previously published grey
literature, expert documents and congress abstracts. Based on Medical Subjects Headings
(MeSH) the keywords used in the search strategy were “fibromyalgia”, “virtual reality”
and “virtual reality exposure therapy” with its synonyms. Based on the particular database,
the Boolean operators “AND”/“OR” were used to combine the keywords and entry terms,
according to PICOS tool of Cochrane Collaboration [42], for the retrieval of reports of
randomized controlled trials (RCTs). Language and publication date filters were not used.
A third expertise author (E.O.-G.) revised the bibliographic search and resolved doubts.
Table 1 shows the search strategy used in each database.
Table 1. Search strategy used in each database.
Databases Search Strategy
PubMed Medline
(fibromyalgia[mh] OR fibromyalgia[tiab] OR fibromyalgia
syndrome[tiab] OR fibromyalgia*[tiab] OR chronic, fatigue
syndrome[tiab]) AND (virtual reality[mh] OR virtual reality[tiab]
OR virtual reality exposure therapy[mh] OR virtual reality
exposure therapy[tiab] OR exergam*)
Web of Science TOPIC: (*fibromyalgia* OR *chronic, fatigue syndrome*) ANDTOPIC: (*virtual reality* OR *exergame*)
SCOPUS
(TITLE-ABS-KEY (“fibromyalgia” OR “fibromyalgia syndrome”
OR “chronic fatigue syndrome”) AND TITLE-ABS-KEY (“virtual
reality” OR “exercises” OR “videogames”))
PEDro Fibromyalgia AND virtual realityFibromyalgia AND exergames
CINAHL Complete
AB (fibromyalgia OR fibromyalgia syndrome OR chronic fatigue
syndrome) AND AB (virtual reality OR exergames
OR videogames)
2.3. Study Selection and Inclusion Criteria
Two blinded reviewers (N.Z.-A. and F.A.N.-E.), independently, screened the titles and
abstracts of all references retrieved in each database. When one of these authors selected an
article during the inclusion phase based on the title and abstract, it was examined in detail.
All disagreements were resolved by a third author (M.C.O.-P.). A study was included in
the present SR when it met all the following inclusion criteria: (1) RCTS or RCT pilot study;
(2) comprised by women with FMS; (3) with at least two groups; (4) of which one group
received VRBT; (5) compared with controls; (6) and reported quantitative data of different
outcomes related with FMS impact (see Section 2.5). The exclusion criteria that were
established included (1) experimental studies without a comparison group and (2) studies
comprising patients with a variety of musculoskeletal disorders (i.e., not only FMS).
2.4. Data Extraction
Two authors (I.C.-P. and E.O.-G.) independently collected data from the included
studies in a standardized Microsoft Excel data-collection form. To resolve disagreements, a
third author was consulted (M.C.O.-P.). We extracted the following data: (1) overall charac-
teristics of the study (authorship and publication date, study design, number of groups,
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total sample size and time since FMS diagnosis); (2) characteristics of the intervention and
control groups (number of participants, mean age, sex, body mass index, intervention and
duration of the intervention in weeks, number of sessions per week and duration of each
session in minutes); (3) data related to the post-intervention outcomes (outcomes assessed,
mean and SD of each outcome in each study and group); and (4) evaluation time sequence
(right at the end of the therapy or follow-period). When a study did not provide statistics
appropriate for performing the meta-analysis, we extracted the median, standard error,
range or interquartile range to be transformed into a SD [42].
2.5. Outcomes
The main outcome assessed in this SR was the impact of FMS, which was assessed
in patients with FMS after receiving VRBT in comparison to other interventions (such
as conventional therapy-based therapeutic exercise (CTBTE) or stretching [ST]) or no
intervention (NI). The Fibromyalgia Impact Questionnaire (FIQ) was selected to assess the
impact of FMS in the selected studies. In addition, other variables assessed in this SR were
pain, dynamic balance, aerobic capacity, fatigue, QoL, anxiety and depression. Different
assessments examining the same outcome were grouped together for analysis (see results
of meta-analyses section).
2.6. Risk of Bias and Methodological Quality Assessment
The PEDro Scale was used to assess the risk of bias of the included studies [43]. The
PEDro Scale comprised 11 items with two answer options (“yes” if the criterion was clearly
satisfied and “no” if the criterion was not satisfied) [44]. The total score could vary across
a range from 0 (high risk of bias) to 10 (low risk of bias), and item 1 was not used for its
relationship with external validity [45].
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE)
assessment [46] was used to analyze the quality evidence of the findings. This scale as-
sesses the risk of bias in each study, inconsistency, indirectness, precision and the risk
of publication bias. All these items, except the risk of bias, were assessed using the
GRADE checklist of Meader et al. (2014) [47] Inconsistency was assessed based on hetero-
geneity level [48]; precision was assessed through the number of participants per study
(large > 300 participants, moderate 300–100 participants and low < 100 participants) and
with the number of studies included (large >10 studies, moderate 10–5 studies and low
< 5 studies) [46]; and indirect evidence was considered to exist in those articles in which
the results were indirectly measured and was scored as “yes” or “no”. Risk of publication
bias is explained in statistical analysis Section 2.7.
Two authors (N.Z.-A. and M.d.R.I.-L.) independently assessed the risk of bias, and
quality evidence and doubts related to this assessment were resolved in consultation with a
third researcher (M.C.O.-P.). The quality evidence of each meta-analysis was downgraded
from high quality by one level for each factor that was found. In the case of the presence of
several limitations, the overall quality level was downgraded by two levels. Finally, the
level of evidence in each meta-analysis was categorized as (1) high: the findings are robust;
(2) moderate: it is possible that new research may change our results; (3) low; the level
of confidence in our pooled effect is very slight; or (4) very low: any estimate of effect is
very uncertain.
2.7. Statistical Analysis
Two authors (E.O.-G. and I.C.-P.) carried out the meta-analysis using Comprehen-
sive Meta-Analysis version 3.0 (Biostat, Englewood, NJ, USA) [49]. Meta-analysis was
conducted only if an outcome measure was provided by at least two studies. To perform
the meta-analysis, we followed the recommendations of Cooper et al. (2009) [50] and to
estimate the effect of VRBT, Cohen’s standardized mean difference (SMD) [51] and its 95%
confidence interval (95% CI) in a random effects model proposed by DerSimonian and
Laird [52] were used. Cohen’s SMD can be interpreted as one of four effect strength levels:
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no effect (SMD 0), small (SMD 0.2–0.4), medium (SMD 0.4–0.7) and large (SMD > 0.8) [53].
In addition, when an outcome was assessed with the same test, we calculated the mean
difference (MD) with the aim of comparing our results to the minimal clinically important
difference (MCID) value for each assessed outcome. The pooled effect of each meta-analysis
is displayed using forest plots [54]. The risk of publication bias was assessed through the
visualization of symmetric (low risk) or asymmetric (high risk) funnel plots [55] using
Egger’s test (where if the p-value < 0.1, there exists a risk of publication bias) [56]. In
addition, the trim-and-fill method was used to estimate the adjusted SMD, taking into
account any possible risk of publication bias [57]. Based on Rothman’s recommendations
for the effect size variation limit in the assessment of confusion bias, when the adjusted
SMD varied more than 10% with respect to the original and raw pooled effects, the qual-
ity level of evidence was downgraded one level, although the funnel plot was slightly
asymmetrical [58]. Finally, the level of heterogeneity was assessed with the Q-test and the
degree of inconsistency (I2) from Higgins et al. [48]. Heterogeneity may be present when
the p-value < 0.1, and it can be categorized as low (I2 < 25%), moderate (I2 between 25–50%)
or large (I2 > 50%) [59,60].
2.8. Additional Analyses
To assess the effect of the use of VRBT alone or combined with CTBTE on the impact of
FMS, we performed a subgroup analysis (VRBT + CTBTE vs. CTBTE or VRBT vs. NI) using
data from RCTs. In addition, a sensitivity analysis was performed using the leave-one-out
method [42,50] that shows how each individual study affected the overall estimate based
on the remaining studies. Finally, a qualitative synthesis was carried out for those variables
that did not report data that could be meta-analyzed but were analyzed in the studies
included in the review.
3. Results
3.1. Study Selection
The PRISMA flow chart (Figure 1) displays the study selection process. One hundred
forty-nine records were retrieved from the initial bibliographical search (145 from databases
and 4 in others additional sources). Seventy-five studies were excluded for duplication,
and 74 references were initially screened by title and abstract. Ten studies were removed
based on title/abstract, and 53 studies did not meet the inclusion criteria. Finally, 11
RCTs [61–71] were included. Specifically, 10 RCTs [61,62,64–71] were included in the
quantitative synthesis, and 2 RCTs [63,67] were included in the qualitative synthesis. One
RCT [67] provided information for quantitative and qualitative synthesis.
3.2. Characteristics of the Studies Included in the Review
All included RCTs were carried out between 2015 and 2021 (2015 [65], 2017 [62,64],
2019 [63,68,70,71], 2020 [61,66,67] and 2021 [69]) in Spain [62–65,67,68,70,71], Turkey [66,69]
and Brazil [61]. The included studies reported data from 535 participants with FMS (100%
women) with a mean age of 51.11 ± 4.2 years old, a mean BMI of 27.27 ± 1.6 kg/m2 and a
mean duration of FMS symptoms of 10.49 ± 5.4 years. Two hundred seventy-nine women
(51.68 ± 3.9 years old) were in the experimental intervention groups receiving VRBT, and
256 participants (50.54 ± 4.6 years old) were in the control intervention groups. In the
experimental group, 10 RCTs used non-immersive VRBT [61–65,67–71] and 1 RCT [66]
used immersive VRBT. In addition, VRBT was used alone in 9 RCTs [61–65,67,68,70,71]
and in combination with CTBTE in another 2 RCTs [66,69]. Regarding the control groups,
in 2 RCTs, women received CTBTE (aerobic exercise [69] and Pilates therapy [66]); in
one RCT [61], women received ST; and in 8 RCTs [62–65,67,68,70,71] participants did
not receive any therapy. The duration of VRBT in weeks was heterogeneous at 3 [65],
7 [61], 8 [62,64,66,69] and 24 weeks [63,67,68,70,71]; the number of sessions per week
was 2 [62–68,70,71] and 3 [61,69] and finally, the duration of each session in minutes was
60 min [61,62,64,65,67,68,70,71], 35 min [69] or 80 min [66]. All assessments were carried
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out to the end of the intervention. Table 2 shows the characteristics of the studies included
in this SR.
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Figure 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart for
the systematic literature search and study selection process. Note: One study (León-Llamas, JL et al.
2020) [67] provided information for quantitative and qualitative synthesis.
3.3. Risk of Bias Assessment of the Studies Included in the Review
The risk of bias scores for 7 RCTs [61–64,68,70,71] were obtained on the PEDro website,
and for four RCTs [65–67,69] it was assessed manually. All included RCTs obtained a score
of at least 5 points. The mean PEDro score was 6.63 ± 0.51 points. The impossibility of
blinding the participants and the therapist and participants’ concealed allocation were the
items involved in the high risk of bias. Table 3 shows the PEDro assessment.
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Table 2. Characteristics of the studies included in the review.
Experimental Group Control Group
Outcomes
Sample Characteristics Intervention Characteristics Sample Characteristics
Authorship
and Date Country K N Ne Age BMI
Evol.
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Table 2. Cont.
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Table 2. Cont.
Experimental Group Control Group
Outcomes
Sample Characteristics Intervention Characteristics Sample Characteristics
Authorship
and Date Country K N Ne Age BMI
Evol.










Spain 2 55 28 54.04 27.36 19.2 ni
VRBT








Spain 3 37 22 54.27 27.1 NR ni
VRBT



















Abbreviations: K, Number of comparisons provided; N, total sample size; Ne, experimental group sample size; BMI, body mass index; Evol, evolution; Ses, sSessions; Min, minutes; Nc, control group sample size;
niVRBT, non-immersive virtual reality; iVR, immersive virtual reality; CTBTEM, conventional therapy based virtual training; ST, stretching exercise; FMS, fibromyalgia syndrome; FIQ, Fibromyalgia Impact
Questionnaire; Anx, anxiety; Dep, depression; VAS, Visual Analogue Scale; TGUGT, Timed Get Up and Go Test; QLI-SP, Quality of Life Index; BPI, Brief Pain Inventory; BDI-II, Beck Depression Inventory II; FSS,
Fatigue Severity Scale; EQ-5D-5L, The Euro Quality of Life Five Dimensions; HADS, Hospital Anxiety and Depression Scale-Anxiety Dimension; HADS-D, Hospital Anxiety and Depression Scale-Depression
Dimension; EEG Signals, electroencephalographic signals.
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Table 3. Methodological quality and risk of bias (PEDro Scores) of the studies included in the review.
Authorship
Items
1 2 3 4 5 6 7 8 9 10 11 TOTAL
Collado-Mateo,
D. et al., 2017a
[62]
N Y N Y N N Y Y Y Y Y 7
Collado-Mateo,
D. et al., 2017b
[64]
Y Y Y Y N N Y Y N Y Y 7
García-Palacios,
A. et al., 2015 [65] Y Y N Y N N Y Y Y Y Y 7
Gulsen, C. et al.
2020 [66] Y Y N Y N N N Y Y Y Y 6
León-Llamas, J.L.
et al., 2020 [67] Y Y N Y N N Y Y Y Y Y 7
Martín-Martínez,
J.P. et al., 2019
[68]
Y Y N Y N N Y Y Y Y Y 7
Polat, M. et al.,
2021 [69] Y Y N Y N N Y Y Y Y Y 7
Silva de
Carvalho, M.
et al., 2020 [61]
Y Y N Y N N Y N Y Y Y 6
Villafaina, S.
et al., 2019a [63] Y Y N Y N N Y Y Y Y Y 7
Villafaina, S.
et al., 2019b [70] Y Y N Y N N Y N Y Y Y 6
Villafaina, S.
et al., 2019c [71] Y Y N N N N Y Y Y Y Y 6
Abbreviations: 1 = eligibility criteria, 2 = random allocation, 3 = concealed allocation, 4 = baseline comparability,
5 = blind subjects, 6 = blind therapists, 7 = blind assessors = 8, adequate follow-up, 9 = intention-to-treat analysis,
10 = between-group comparisons, 11 = point estimates and variability, Note = eligibility criteria item does not
contribute to total score, Y = Yes, N = No.
3.4. Quantitative Synthesis
Ten RCTs [61,62,64–71] with 34 independent comparisons providing data for 485 women
with FMS (50.92 ± 4.4 years old, mean BMI of 27.27 ± 1.59 kg/m2 and a mean duration of
symptoms of 10.49 years) were included in the quantitative synthesis. Table 4 shows the
main findings of each meta-analysis.
3.4.1. Impact of FMS Symptoms
Six RCTs [61,62,65,66,69,71] provided data from 249 women with FMS (49.3 ± 5.06 years old),
in which the impact of FMS was assessed using the FIQ-total score. Moderate-quality ev-
idence suggested a medium effect of VRBT on FIQ scores (SMD −0.62, 95% CI −0.93
to −0.31; p < 0.001) (Figure 2) showing a reduction of FIQ of −9.96 (95% CI −13.64 to
−6.28) compared to control, favored VRBT. No risk of publication bias (Egger p = 0.9) or
heterogeneity (I2 5.18%) were found. Sensitivity analysis did not reported variation.
Subgroup analysis showed a reduction in FIQ scores favors VRBT (MD −9.01, 95%
CI −14.13 to −3.88) compared to NI and in the combined use of VRBT + CTBTE (MD
−9.86, 95% CI −17.65 to −2.06) in comparison to CTBTE, with low- and very low-quality
evidence, respectively.
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Table 4. Main findings in meta-analyses.
Outcomes
Summary of Findings Quality of Evidence (Grade)
Pooled Effect
Het Publication Bias














Symptoms 6 249 41.5 −0.62 −0.93 to −0.31 5.2% (p = 0.4) Sym (p = 0.9) −0.62 0% Medium No No Yes No Moderate
Pain 6 267 44.5 −0.45 −0.69 to −0.21 0% (p = 0.52) Asym (p = 0.2) −0.72 28% Medium No No Yes Yes Low
Dynamic
Balance 3 168 56 −0.76 −1.12 to −0.39 4.4% (p = 0.35) Sym (p = 0.52) −0.75 0% Medium No No Yes No Low
Aerobic
Capacity 5 164 32.8 0.32 0.004 to 0.63 0% (p = 0.57) Asym (p = 0.31) 0.36 12% Medium No No Yes Yes Low
Fatigue 4 153 38.5 −0.58 −1.02 to −0.14 5.4% (p = 0.37) Asym (p = 0.09) −0.48 20% Medium No No Yes Yes Low
Quality of Life 5 246 49.2 0.55 0.3 to 0.81 0% (p = 0.73) Sym (p = 0.9) 0.52 0% Medium No No Yes No Moderate
Anxiety 3 137 45.7 −0.47 −0.91 to −0.03 0% (p = 0.32) Asym (p =0.2) −0.57 22% Medium No No Yes Yes Very-Low
Depression 4 196 49 −0.46 −0.76 to −0.16 4.6% (p = 0.4) Asym (p =0.14) −0.52 13% Medium No No Yes Yes Low
Abbreviations: GRADE = grading of recommendations assessment, development, and evaluation, Het = heterogeneity, K = number of comparisons, N = total sample size, Ns = Participants per study, SMD =
Cohen’s standardized mean difference, 95% CI = 95% confidence interval, I2 = degree of inconsistency p = p-value; Adj = adjusted, % of var = percentage of variation, Indirect = indirectness, Imprec = imprecision,
Pub bias = publication bias, Sym = symmetric, Asym = asymmetric.
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3.4.2. Pain
Six RCTs [61,62,65,66,69,70] provided data on 267 women with FMS (49.28 ± 5.04 years old)
using the VAS, the pain dimension on the FIQ and the Brief Pain Inventory (BPI). Low-
quality evidence showed a moderate effect of VRBT (SMD −0.45, 95% CI −0.69 to −0.21; p
< 0.001) compared to controls (Figure 3). The risk of publication bias may be considered
(Egger p = 0.2 and trim-and-fill variation of 28%) without heterogeneity (I2 0%). Sensitivity
analysis showed a variation of 17% when Collado-Mateo [62] was removed.
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Subgroup analysis showed low-quality evidence of a medium effect of VRBT in
comparison with NI (SMD −0.64, 95% CI −1.18 to −0.11), favored VRBT.
3.4.3. Dynamic Balance
Three RCTs [64,68,71] reported data from 168 women with FMS (53.36 ± 0.74 years
old), which assessed dynamic balance using the Timed Get Up and Go Test (TGUGT)
and the 10-Step Chair Test (SCT). Low-quality evidence of a medium-high effect of VRBT
(SMD −0.76, 95% CI –1.12 to −0.39; p < 0.001) on dynamic balance in comparison with NI
was found (Figure 4). No risk of publication bias (Egger p = 0.52) and low heterogeneity
were present (I2 4.35%). There was an estimated variation of 20% with respect to the
original SMD when Villafaina was excluded [71]. In this outcome, subgroup analysis was
not performed due to lack of studies for other comparisons.
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3.4.5. Fatigue
Four RCTs [61,62,66,69] reported data from 153 women with FMS (47.86 ± 5.62 years old)
that assessed fatigue through the FIQ fatigue domain and Fatigue Severity Scale (FSS).
Low-quality evidence showed a medium effect of VRBT (SMD −0.58, 95% CI −1.02 to
−0.14; p = 0.01) on fatigue compared with other interventions or NI (Figure 6) with low
heterogeneity (I2 5.4%). Risk of publication bias was present (Egger p = 0.09 and variation
of 20% with the trim-and-fill method). Sensitivity analysis showed a variation of 31% whe
excluding Polat [69].
Subgroup analysis showed low-quality evidence of a reduction in fatigue (MD −2.21
95% CI −4.33 to −0.1) when VRBT was used in combination with CTBTE compared to
CTBTE alone, favored VRBT intervention.
3.4.6. Quality of Life
Five RCTs [62,65,66,69,70] provided data from 246 women with FMS (48.8 ± 5.1 years
old) that assessed QoL with the EuroQol-5D, QoL Index and SF-36. Moderate-quality
evidence of a medium effect of VRBT (SMD 0.55, 95% CI 0.3 to 0.81; p < 0.001) on QoL
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was shown in comparison to CTBTE or NI (Figure 7). No risk of publication bias or
heterogeneity was found (I2 0%). Sensitivity analysis did not show variation.
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+ CTBTE (SMD 0.6 , 95% CI 0.12 to 1.2) compared to NI and CTBTE, respectiv ly,
with lo -quality evidence.
3.4.7. Anxiety and Depression
Anxiety was assessed in 3 RCTs [61,62,69] that provided data from 137 women with
FMS (49.65 ± 4.74 years old) using the FIQ anxiety domain and Hospital Anxiety and De-
pression Scale, anxiety dimension (HADS-A). Very low-quality evidence of a medium effect
of VRBT (SMD −0.47, 95% CI −0.91 to −0.03; p = 0.037) in comparison to other interven-
ions or NI (Figure 8) without heteroge eity (I2 0%) and with a possible risk of publication
bias (trim-and-fill variation of 22%). Sensitivity analysis showed a variation of 36% when
excluding Polat [69]. In this outcome, subgroup analysis was not performed due to lack of
studies for other comparisons (only one study was included per specific comparison).
Four RCTs [61,62,65,69] provided data from 196 women with FMS (49.86 ± 4.02 years
old) in which depression was assessed using the FIQ depression domain, HADS depression
dimension and Beck Depression Inventory (BDI-II). Low-quality evidence of a medium
effect of VRBT (SMD −0.46, 95% CI −0.76 to −0.16; p = 0.003) was shown compared to other
interventions or NI (Figure 9). A possible risk of publication bias would be considered due
to a variation of 13% with the trim-and-fill method (Egger p = 0.14) and low heterogeneity
(I2 4.59%). Sensitivity analysis displayed a variation of 19% with respect to the original
pooled effect when Silva-Carvalho was excluded [61]. A subgroup analysis could only be
J. Pers. Med. 2021, 11, 1167 15 of 22
performed in the comparison VRBT vs. NI, showing a medium effect (SMD −0.56; 95% CI
−0.97 to 0.15; p = 0.008).
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4. Discussion
FMS is a chronic disease characterized by widespread muscle pain that reduces
functional capability and QoL. In addition to other therapies, such as pharmacotherapy [72],
balneotherapy [73] or physical exercise [74,75], VRBT has emerged as a new therapy that
can reduce the impact of FMS symptoms. The present study proposed to compile the
scientific evidence published to date to analyze the effectiveness of VRBT on the impact of
FMS and in ot er related outcomes.
One of the most important impairm nts of FMS is its impact on ADLs, which is mainly
assessed with the FIQ [76]. Our results sug ested that VRBT is effec ve to reduce the
impact of FMS symptoms on ADLs. The significant decrease in FIQ scores (approximately
10% of the total score both with VRBT alone or combined with CTBTE) would be related
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to the fact that VRBT is an active therapy that requires continuous body movements,
which can combine the effect of multisensory stimulation and physical exercise. VRBT is
considered a positive, different and motivating experience that directly impacts well-being
and reduces the perception of the severity of symptoms. These results support the fact
that VRBT may be considered a real therapeutic option to reduce the impact of FMS. In
addition, subgroup analysis according to specific comparisons, showed that to VRBT is
better than or NI (also called, UC) and the combined use of VRBRT with CTBTE is better
that to perform only CTBTE. Between these two comparisons, VRBT with CTBTE is the
best therapeutic option to improve the FIQ in women with FMS. It can allow personalize
therapies combining different VR videogames and CTBTE protocols adapted for each
women with FMS.
Some studies have suggested that VRBT is a novel approach in the field of orthopedic
rehabilitation [77], in the management of acute or chronic pain [78] and in neuropathic
pain control [79], among others. Our findings showed that VRBT could be effective as a
non-pharmacological alternative intervention to reduce pain in women with FMS. Sub-
group analysis revealed that in comparison with UC, VRBT is effective to reduces the pain
level. The high levels of body pain that patients with FMS suffer from are supported by
CS, which can be enhanced or maintained by supraspinal processes involving cognitions
and focused attention on the sensation of pain [80]. It has been described that emotions
that are directly connected to the limbic system can modulate pain through descending
pathways [81]. To interact with VRBT as a method of distraction in which many neuro-
physiological connections occur between the visual and somatosensory systems might
divert attention, leading to a slower response to incoming pain signals [78,81]. Likewise,
a pleasant playful experience would lead to positive emotions capable of improving en-
dogenous nociceptive inhibition. The continuous pain experience in patients with FMS
produces muscle debility that together with negative emotions when moving can favor
the appearance of kinesiophobia that reduces active movement and muscle tone, thereby
increasing fatigue and pain [82]. VRBT requires autonomous movement of different body
parts that can increase muscle tone and the perception of pain-free movement favoring
the elimination of restrictions to movement included in the cerebral body scheme due to
continued pain. Performing CTBTE through VR devices could provide greater adherence
by using exercises adapted to different levels of progression. VR-based exercises could be
more enjoyable and stimulating, facilitating implementation in subjects with FMS who
have difficulty adhering to CTBTE.
Balance disorders appear in women with FMS, increasing the risk of falls [4]. A recent
meta-analysis showed that women with FMS develop balance disorders [83] resulting in
a high risk of falls. Some studies have found a reduction in brain grey matter in which
vestibular, visual and somatosensory information is processed and integrated to produce
a balanced response [84]. For this, it is necessary to implement therapies that provide
the patient with multisensory stimulation at the same time that the patients are forced to
actively work. Our results suggested that VRBT improves dynamic balance in subjects with
FMS. VRBT is an active therapy that requires engaging in physical activities during the
sessions, and the findings obtained were similar to those in different reviews that assessed
the effects of physical exercise or Tai Chi to increase the balance in FMS women [25,85].
According to Villafaina, S. et al., 2019 [63], VRBT produces changes in different brain areas
and increases the grey matter and EEG signals in the frontal, parietal, temporal and occipital
lobes, some of which are responsible for integrating the balance information needed to
respond to a destabilizing stimulus or Earth’s gravitational force. The continued and active
work in the standing position with a high level of multisensory stimulation by VR devices
improve the neuromuscular efferent responses to maintain balance. Finally, some patients
with FMS take anxiety and depression drugs, such as antipsychotics, that can increase the
risk of falls [86]. VRBT includes virtual physical exercise to improve muscle tone, postural
afferences and neuromotor responses to an antigravitational stimulus, reducing the risk
of falls.
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Women with FMS reported a decreased aerobic capacity, which could have a negative
impact on functional capacity and consequently on QoL. Our findings showed an improve-
ment in aerobic capacity in women who were exposed to VRBT. VRBT could provide the
training of representative tasks included in ADLs that require less muscle strength and
allow individuals to perform the activity for longer periods of time, which increases the
cardiorespiratory fitness of these patients [7].
Generalized fatigue induces a sedentary lifestyle in women with FMS, which reduces
aerobic capacity [87]. For this reason, women with FMS can perceive higher levels of
fatigue during the performance of ADLs. Our results suggested that VRBT is useful for
reducing fatigue in women with FMS, and there was a greater effect when combined with
exercise. Our results are in line with a recent review in which VRBT has been postulated
to be an effective method to reduce fatigue in different groups of patients [88]. In recent
years, numerous therapies have emerged for the treatment of fatigue in FMS; however, the
provided evidence has not been sufficient to unify criteria regarding the most appropriate
treatment [89]. In this sense, VRBT may be an effective therapy to reduce fatigue because it
is a customized method that increases distraction and prevents patients from being aware
of fatigue.
In our study, we report that QoL improves after to use of VRBT. Restoring and
balancing physical activity is a challenge in patients with FMS and chronic pain. Low
mood, pain, and fatigue decrease the willingness to perform ADLs, causing low motivation
and a poor sense of self-efficacy and QoL. Recent studies have shown that VRBT improves
mood states, positive emotions, motivation, and self-efficacy in FMS patients [39], which
should have a positive impact on QoL. A recent review postulated that the regulation of
emotions through VRBT could be an effective method to increase QoL and personal well-
being [90]. In addition, several studies have analyzed the efficacy of VRBT in combination
with other therapies on QoL in different pathologies, such as rheumatic and orthopedic
diseases, finding beneficial effects [77].
Our results showed that the levels of anxiety and depression improved after the use
of VRBT in women with FMS, although a major effect was found on depression outcomes.
Physical exercise in FMS patients has previously been shown to improve anxiety [91] and
depression [92]. In recent years, VRBT has been considered a new and cost-effective tool to
complement psychological treatments [93]. Our findings are consistent with a recent meta-
analysis that assessed the effect of VRBT on anxiety and depression, finding a reduction in
anxiety and depression after the application of VRBT in comparison to control conditions
(e.g., waitlist, placebo, relaxation or NI) [94].
One study included in our review found significant relationships between pVO2 and
the left and right regions of the hippocampus and the left and right regions of the amygdala
after training with VRBT [67]. These findings may be in line with the results of a study
that analyzed neural activity and respiratory frequency in anticipation of anxiety. The
activation of this area participates in the enhancement of respiratory frequency. Electric
current sources were found in the left amygdala in the most anxious subjects [95]. The
authors pointed out the need to study the relationship between the aerobic system and
the amygdala, since women with FMS constitute a population associated with anxiety
symptoms [96,97]. Findings from Villafaina, S et al. 2019 [63] indicated that VRBT can
produce changes in the dynamics of the brain that could be related to an increase in
cerebral blood flow. These results are particularly relevant to FMS patients because they
frequently have altered cerebral blood flow variability and velocity [98,99], as well as
impaired cognitive function [100]. Thus, VRBT in FMS patients could increase cerebral
blood flow and, consequently, cognitive function. Additionally, the intervention in this
study was more effective in the group with a shorter duration of symptoms, showing
between-group differences in some frontal and temporal areas. Previous studies have
shown that a longer duration of FMS symptoms predicts lower FIQ scores, which shows
that patients who have suffered from FMS symptoms for short periods of time may be more
J. Pers. Med. 2021, 11, 1167 18 of 22
severely affected by the disease [101]. These results suggested that VRBT could counteract
severe FMS symptoms.
Our results may be considered to have some limitations. First, the low number of
studies included may make generalization of our findings difficult. Related with the
generalization of our findings a limitation is that our findings are applied to women with
an age that varied between 38 and 55 years old (mean of 51.4 years old) and BMI between
25 to 28 (mean of 27.7). It would be important to perform new studies in all groups of
age. Second, the impossibility of blinding the therapy to participants increased the risk of
selection bias. Third, it is important to consider the possible risk of publication bias that
may have reduced the reported effects of therapy. Another limitation was the low number
of participants per study, which reduced the precision level of our findings. Besides, it is
important to highlight that the large variations in sensitivity analysis may have affected the
quality of our findings. Finally, it is important to remark that all studies were performed in
Spain, Turkey or Brazil and it can affect to the generalization of our findings. It would be
necessary to perform studies in more countries to increase the application of our findings.
5. Conclusions
This is the first SR with meta-analysis that demonstrates the effect of VRBT in women
with FMS in reducing the health impact of symptoms of FMS, in short-term follow up.
Our results showed an effect of VRBT in comparison to other interventions or NI and
favored VRBT intervention based on the impact of FMS, pain, dynamic balance, aerobic
capacity, fatigue, QoL, anxiety and depression. In addition, when VRBT was combined
with CTBTE and compared to CTBTE alone, our findings showed a large effect of VRBT +
CTBTE intervention on the measures of the impact of FMS fatigue and QoL. However, it is
necessary to conduct further research on this topic, while increasing the sample size and
extending the assessments to the long term.
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